Let’s make a difference together
Everyone at Mycovia embodies our core values of respect, integrity, perseverance, innovation, quality, and excellence every day. We seek like-minded partners to help us transform healthcare and make a meaningful difference in patients’ lives.
This includes providing global access through development and commercialization.
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Mycovia partnered with Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) in an exclusive agreement to develop and commercialize oteseconazole in China, including mainland China, Hong Kong, Macau, and Taiwan. Hengrui has completed its Phase 3 clinical study of oteseconazole in acute VVC and enrollment started in September 2021 for its Phase 3 clinical study of oteseconazole for RVVC in China, further fulfilling the unmet medical needs of women across the globe.
Read more about this partnership here
Gedeon Richter Plc.
Mycovia has an exclusive license and development and technology transfer agreement with Gedeon Richter Plc., based in Budapest, Hungary, to commercialize and manufacture oteseconazole in Europe, Latin America, Australia, Russia, and other Commonwealth of Independent States (CIS) countries.
Read more about this partnership here
Join the journey
We’re proud to be making a difference in women’s health and are eager to partner with others who share this same drive.
